• news.cision.com/
  • Orexo/
  • Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management
English

Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management

Report this content

  • The Covid-19 pandemic has highlighted the urgent need for additional resources to prevent overdose deaths, which have reached an all-time high[1]

  • modia™ can help those with opioid use disorder by providing access to quality, evidence-based interventions and behavioral health services
     

MORRISTOWN, NJ, US, February 10, 2021: Orexo, a Swedish pharmaceutical company,
will collaborate with ApexB.io and Magellan Rx Management to further research on the use of modia™, a digital therapeutic designed for individuals with opioid use disorder (OUD), by establishing a novel, real-world evidence approach. modia™, offers individuals with OUD access to tailored, interactive psychotherapy interventions through their mobile device or computer.

This relationship will provide further data behind the need for an easily accessible digital treatment option for OUD. This is a critical time for such a treatment option as the Centers for Disease Control and Prevention (CDC) recently called for expanded efforts related to the prevention of overdose deaths during the pandemic. The US has experienced more than 83,000 deaths as a result of overdoses – the highest ever recorded in a 12-month period.[1]

“The Covid-19 pandemic has had a profound impact on opioid use in the US, accelerating the number of overdose deaths in the last year alone,” said Dennis Urbaniak, Executive Vice President Digital Therapeutics, Orexo US. “It’s our duty to do everything in our power to bring modia™ to market quickly and ahead of schedule so we can aid in the effort to save lives. We’re grateful to collaborate with ApexB.io and Magellan Rx Management who are ready to help us do just that.”

A combination of drug and therapy treatment, or medication-assisted treatment (MAT), is recommended for individuals with OUD, however, only 36 percent of healthcare providers report an adequate number of counselors in their area.[2]  With this in mind, modia™ was designed to help close the gap in care by providing access to quality, evidence-based therapeutic interventions rooted in cognitive behavioral therapy and other effective psychotherapeutic techniques.

Last year, Orexo also accelerated the launch of two additional digital therapeutics, deprexis® and vorvida®, which help address depression and problematic or harmful alcohol use respectively, in response to increased mental illness during the Covid-19 pandemic.

The first payers have agreed to provide participants to the trial and additional payers are expected to join in the future. A broad launch of modia™ in the US is expected in H2 2021.

For more information:

Orexo DTx Contact:

Dennis Urbaniak

EVP Digital Therapeutics

Phone: +1 (0)855 982 7658

E-mail: us.media@orexo.com


About Orexo DTx

Orexo DTx is the digital health arm of Orexo AB, a pharmaceutical company that develops and commercializes improved pharmaceuticals and digital therapies. The company addresses unmet needs within the growing space of mental health and substance use disorders. Orexo DTx was created in Q4 of 2019 and in the second half-year of 2020 vorvida®, for alcohol misuse, and deprexis®, for depression, were launched in the US while, modia™, for opioid use disorder, is expected to be launched in 2021. All digital therapies are in partnership with the GAIA group.

Orexo DTx’s mission is to redefine treatment of addiction by offering clinically validated digital therapeutics to ensure more successful treatment for patients and cost-effective solutions for payers.

The digital products are commercialized by Orexo DTx initially in the US where Orexo also commercializes its lead product ZUBSOLV® (buprenorphine and naloxone) sublingual tablets (CIII) for treatment of opioid use disorder.

Orexo is listed on the Nasdaq Stockholm Mid Cap (ORX) and is available as ADRs on OTCQX (ORXOY) in the US. The company is headquartered in Uppsala, Sweden, where research and development activities are performed.

For more information about Orexo please visit, www.orexo.com. You can also follow Orexo on Twitter, @orexoabpubl, LinkedIn and YouTube.

About ApexB.io

Apex health is a boutique consulting company providing strategic guidance and analytics to life-sciences and healthcare companies to help understand patient journey, conduct real world research and achieve optimal market access. ApexB.io team has expertise in design and launch of digital therapeutic solution that improve clinical outcomes and enhance patient engagement. ApexB.io leverages it’s propriety curio digital therapeutic platform for “end to end “technology solution for Digital Therapeutics that provides workflow integration and data capture. ApexB.io has multiple industry as well as academic partnerships to conduct real world studies that provide insights into patient journey and unmet need.

About Magellan Rx Management

Magellan Rx Management, a division of Magellan Health, Inc., is shaping the future of pharmacy. As a next-generation pharmacy organization, we deliver meaningful solutions to the people we serve.  As pioneers in specialty drug management, industry leaders in Medicaid pharmacy programs and disruptors in pharmacy benefit management, we partner with our customers and members to deliver a best-in-class healthcare experience. 

 

[1] June 2019 – June 2020 (https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm#dashboard)

[2] Researchers specifically surveyed physicians actively prescribing buprenorphine (N = 1174)

Subscribe